Y.D. More Investments Ltd Buys 377,179 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Key Points

• Y.D. More Investments Ltd increased its stake in OPKO Health, acquiring an additional 377,179 shares, bringing its total ownership to approximately 1,772,947 shares, valued at around $2.97 million.
• OPKO Health reported a negative earnings per share (EPS) of ($0.19) for the quarter, falling short of analysts' expectations and marking a 13.9% decline in revenue year-over-year.
• Institutional investors collectively control 64.63% of OPKO Health's stock, reflecting strong interest from major financial entities in the biotechnology company.

Y.D. More Investments Ltd lifted its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 27.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,772,947 shares of the biotechnology company's stock after acquiring an additional 377,179 shares during the quarter. Y.D. More Investments Ltd owned approximately 0.22% of OPKO Health worth $2,971,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Oak Thistle LLC purchased a new position in OPKO Health during the 1st quarter worth $26,000. Cerity Partners LLC purchased a new position in shares of OPKO Health during the first quarter valued at $36,000. Pallas Capital Advisors LLC bought a new stake in shares of OPKO Health in the first quarter valued at about $43,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 12,417 shares in the last quarter. Finally, Zacks Investment Management purchased a new stake in OPKO Health in the fourth quarter worth about $49,000. Institutional investors own 64.63% of the company's stock.

OPKO Health Stock Up 0.8%

NASDAQ:OPK opened at $1.27 on Thursday. The company's 50-day simple moving average is $1.34 and its 200-day simple moving average is $1.47. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. OPKO Health, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The stock has a market capitalization of $1.01 billion, a P/E ratio of -5.08 and a beta of 1.19.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The firm had revenue of $156.80 million for the quarter, compared to analysts' expectations of $165.74 million. During the same period in the previous year, the company earned ($0.01) EPS. The company's revenue was down 13.9% on a year-over-year basis. On average, equities analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating on the stock. LADENBURG THALM/SH SH raised shares of OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. Barrington Research restated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a report on Thursday, May 1st. Finally, Wall Street Zen cut OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.